Azithromycin (Zithromax®)

James M. McCarty
Hilltop Research Centers, Fresno, CA

ABSTRACT

Azithromycin (Zithromax®, Pfizer, Inc., New York, NY) is a 15-membered-ring macrolide and the first azalide antibiotic. It is distinguished from other macrolides by its rapid and extensive penetration into intracellular and interstitial tissue compartments, accompanied by prolonged tissue and serum half-lives. Azithromycin shares the gram-positive activity of erythromycin but is more potent against gram-negative organisms. For urethritis and cervicitis caused by Chlamydia trachomatis, azithromycin is effective and well tolerated in a single dose of 1 g, a regimen recommended by the CDC. A 5-day dosage regimen is available for the treatment of community-acquired respiratory-tract and skin and skin-structure infections caused by susceptible organisms. Azithromycin provides short-duration, high-compliance, cost-effective regimens that should improve outcomes.

KEY WORDS
Azalide, urethritis, cervicitis, Chlamydia trachomatis

Azithromycin (Zithromax®, Pfizer, Inc., New York, NY), the first azalide antibiotic, has been approved for the single-dose treatment of nongonococcal urethritis and cervicitis due to Chlamydia trachomatis. In addition, azithromycin is useful in a 5-day regimen for the treatment of indicated respiratory-tract and skin and skin-structure infections (unpublished data, Pfizer, Inc., 1996).

C. trachomatis is the most common sexually transmitted pathogen in the United States. An obligate intracellular parasite, C. trachomatis is the leading cause of nongonococcal urethritis and epididymitis in men under 35 years of age. In women, it causes mucopurulent cervicitis, urethral syndrome, and pelvic inflammatory disease (PID).

The health-care costs of C. trachomatis infections are substantial. In 1990, the direct and indirect costs incurred with PID and PID-associated ectopic pregnancy and infertility—medical problems frequently arising from untreated, uncomplicated chlamydial infections—were estimated to be $4.2 billion.

The treatment of genital chlamydial infections has been difficult. Tetracycline or doxycycline administered orally for 7 days has been widely prescribed as a first-line agent for chlamydial urethritis and cervicitis, although the treatment is limited by mild, bothersome side effects and frequent dosing that can result in poor compliance. In addition, both tetracycline and doxycycline are contraindicated in pregnant patients. Among the macrolides, erythromycin has been used in pregnant women and in patients intolerant of tetracyclines, although it has been poorly tolerated in dosages shown to be clinically effective against C. trachomatis infection.

CHEMISTRY

Azithromycin is a 15-membered-ring macrolide that differs from erythromycin by the presence of a methyl-substituted nitrogen in the macrolide ring.

Address correspondence/reprint requests to Dr. James M. McCarty, Hilltop Research Centers, 6079 N. Fresno #101, Fresno CA 93710.

Antimicrobial Symposium

Received July 2, 1996
Accepted July 16, 1996
TABLE I. Approved indications for azithromycin

<table>
<thead>
<tr>
<th>Infection</th>
<th>Pathogens</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nongonococcal urethritis and cervicitis</td>
<td>Chlamydia trachomatis</td>
<td>1 g x 1</td>
</tr>
<tr>
<td>Acute bacterial exacerbation of chronic</td>
<td>Streptococcus pneumoniae</td>
<td>500 mg x 1 day, 250 mg x 4 days</td>
</tr>
<tr>
<td>obstructive pulmonary disease</td>
<td>Haemophilus influenzae</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moraxella catarrhalis</td>
<td></td>
</tr>
<tr>
<td>Community-acquired pneumonia*</td>
<td>S. pneumoniae</td>
<td>500 mg x 1 day, 250 mg x 4 days</td>
</tr>
<tr>
<td></td>
<td>H. influenzae</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S. pyogenes</td>
<td></td>
</tr>
<tr>
<td>Pharyngitis and tonsillitis*</td>
<td>S. pneumoniae</td>
<td>500 mg x 1 day, 250 mg x 4 days (adults)</td>
</tr>
<tr>
<td></td>
<td>H. influenzae</td>
<td>12 mg/kg x 5 days (children)</td>
</tr>
<tr>
<td></td>
<td>S. pyogenes</td>
<td>10 mg/kg x 1 day, 5 mg/kg x 4 days (children)</td>
</tr>
<tr>
<td>Acute otitis media</td>
<td>S. pneumoniae</td>
<td></td>
</tr>
<tr>
<td></td>
<td>H. influenzae</td>
<td></td>
</tr>
<tr>
<td></td>
<td>M. catarrhalis</td>
<td></td>
</tr>
<tr>
<td>Uncomplicated skin and skin-structure</td>
<td>Staphylococcus aureus</td>
<td>500 mg x 1 day, 250 mg x 4 days</td>
</tr>
<tr>
<td>infections</td>
<td>S. pyogenes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S. agalactiae</td>
<td></td>
</tr>
</tbody>
</table>

*Outpatient pneumonia of mild severity.

In contrast, clarithromycin and dirithromycin are 14-membered ring macrolides that are analogs of erythromycin.7,8

MECHANISM OF ACTION

Azithromycin, like erythromycin, produces its antibacterial effects by inhibiting bacterial protein synthesis through binding to the 50S ribosomal subunit of susceptible organisms.9

PHARMACOKINETICS

Azithromycin is distinguished from erythromycin by its unique cellular kinetics, which include rapid and extensive penetration into intracellular and interstitial tissue compartments and high and sustained tissue levels accompanied by relatively low serum levels. The absorption of azithromycin is generally more predictable than that of erythromycin, producing higher tissue and intracellular concentrations.8,10,11 After absorption, azithromycin is distributed rapidly from serum.7

The bioavailability of azithromycin is 37%.12 The elimination half-life [36–40 h, as determined 24–72 h after a 500-mg intravenous (IV) dose] is more than 10-fold that of other available macrolides.7,12 The concentration of azithromycin in most tissues exceeds that in serum by 10- to 100-fold.12 The projected tissue levels in the prostate or uterus following a single 1-g dose remain well above the minimum inhibitory concentration for 90% (MIC90) of C. trachomatis isolates for as long as 10 days (Fig. 1).12,13 In women who received a single 500-mg oral dose of azithromycin 24–96 h before surgery, high drug concentrations were found in gynecologic tissue up to 96 h after administration.14 The mean maximum concentration 24 h after dosing was 1.44 μg/g, and the estimated tissue half-life was 67 h. The high, sustained concentrations of azithromycin in gynecologic tissue result in the presence of drug above the MIC90 throughout the long life cycle of C. trachomatis.

Delivery by phagocytes enhances the concentrations of azithromycin at sites of infection. The uptake by polymorphonuclear leukocytes (PMLs) and alveolar or peritoneal macrophages is rapid.15 After 2 h of incubation, the intracellular or extracellular concentration ratio was 79 in human PMLs and 62 in murine peritoneal macrophages, compared with erythromycin ratios of 16 and 4, respectively. After 24 h, azithromycin was concentrated 10-fold higher than erythromycin in human PMLs and 26-fold higher in murine peritoneal macrophages. One hour after the removal of extracellular erythromycin, 85% of the accumulated stores were released. In contrast, the removal of extracellular azithromycin resulted in a slow release from intracellular stores (only 19% after 1 h). The exposure of the cells to bacteria enhanced the release of azithromycin from phagocytes.

The significance of the sustained tissue and intracellular concentrations of azithromycin is reflected in its dosage schedule. Azithromycin is administered in a single 1-g dose to patients with uncomplicated urethritis or cervicitis due to C. tra-
Azithromycin is highly active against erythromycin-susceptible, gram-positive organisms because of a
common mechanism of action. In recent surveys of bacterial pathogens in the United States, the rates of susceptibility to azithromycin and erythromycin were virtually identical for clinical isolates of Streptococcus pneumoniae, S. pyogenes, S. agalactiae, and methicillin-susceptible Staphylococcus aureus.

Azithromycin is substantially more potent than other macrolides against several clinically important gram-negative pathogens, including Haemophilus influenzae and Moraxella catarrhalis as well as Mycoplasma pneumoniae.

In vitro studies have shown that azithromycin and erythromycin have comparable activity against Chlamydia trachomatis. The MICs for azithromycin ranged from 0.03 to 0.5 μg/ml in these studies, compared with 0.03 to 1.0 μg/ml for erythromycin.

**CLINICAL APPLICATIONS**

The approved indications and dosage schedules for use of azithromycin are summarized in Table 1. Recent clinical trials have shown that azithromycin is effective and well tolerated when administered as a single dose (1 g) in patients with uncomplicated urethritis or cervicitis due to C. trachomatis.

In a randomized, comparative study, men attending a sexually transmitted disease (STD) clinic who had positive cultures for C. trachomatis received either a single 1-g dose of azithromycin or doxycycline, 100 mg twice daily for 7 days. After 4 weeks, the chlamydial cultures were negative for 43 of 44 patients given azithromycin and 48 of 49 patients given doxycycline. Azithromycin was very well tolerated.

A recent double-blind, multiclinic trial compared single-dose azithromycin with the standard 7-day doxycycline therapy in men with symptomatic nongonococcal urethritis. The cumulative clinical cure rate was 81% among azithromycin recipients and 77% for doxycycline recipients. The cure rates were comparable when patients were stratified by the presence or absence of infection with C. trachomatis prior to therapy. Among those with positive baseline cultures, the overall microbiologic cure rates were 83% [95% confidence interval (CI), 65–94%] for azithromycin-treated patients and 90% (95% CI, 68–98%) for doxycycline-treated patients. Gastrointestinal side effects, the most common adverse experiences with both azithromycin and doxycycline, occurred in 19% and 26% of patients, respectively.

In a multiclinic trial, 3299 women and 158 men with uncomplicated genital infections (urethritis or cervicitis) and antigen tests positive for C. trachomatis were randomly assigned to receive oral doses of either azithromycin (1 g once) or doxycycline (100 mg orally twice daily for 7 days). Only the patients subsequently determined to have cultures showing C. trachomatis at baseline were evaluated. Bacteriologic eradication was achieved in 96% of the evaluable patients given single-dose azithromycin, compared with 98% of those treated with doxycycline. Among the patients evaluated 21–35 days after treatment began, the eradication rates were 100% with azithromycin and 99% with doxycycline.

Treatment-related side effects were reported in 17% of azithromycin recipients and in 20% of doxycycline recipients. Gastrointestinal symptoms were the most common side effects in each group. Except for 1 azithromycin-treated patient with nausea, the symptoms were mild or moderate in severity.

The efficacy and safety of azithromycin in pregnant women with chlamydial cervicitis have been compared with those of erythromycin. Patients were randomly assigned to receive erythromycin or azithromycin and requested to complete questionnaires identifying adverse events. The cure rates were similar with both treatments. All patients in the erythromycin group, however, reported 2 or more gastrointestinal side effects, compared with none in the azithromycin group. In addition, 5 of 15 erythromycin-treated patients were intolerant of the 500-mg 4-times-daily dosage, requiring a reduction to 250 mg to complete the treatment course. No azithromycin-treated patients failed to tolerate the single 1-g oral dose. These findings suggested that azithromycin is an effective alternative to erythromycin in pregnant patients who are intolerant of erythromycin or noncompliant because of gastrointestinal side effects.

In randomized, multicenter trials in adults with community-acquired respiratory-tract infections, azithromycin administered in a 5-day dosage regimen was compared with the standard 10-day regimens of other agents. In all studies, the clinical and bacteriologic efficacy of azithromycin was similar to that of the comparative agents. The infections included acute bacterial exacerbation of chronic obstructive pulmonary disease (chronic bronchitis), mild pneumonia suitable for outpatient oral therapy, and acute pharyngitis or tonsillitis (Table 1).
A multicenter trial in patients with uncomplicated skin and skin-structure infections—predominantly cellulitis or abscesses—showed that azithromycin administered once daily for 5 days was effective clinically and bacteriologically. The strains of *S. aureus* and *S. pyogenes* were the most common bacterial isolates.

**COST**

For the treatment of genital chlamydial infections, azithromycin (1 g once) is more cost-effective than the 7-day regimens of doxycycline. In the treatment of indicated respiratory-tract and skin and skin-structure infections, 5-day azithromycin therapy has among the lowest cost per treatment of any branded antibiotic. The cost comparisons among antimicrobial agents should consider the expected rates of compliance and expenditures for side effects or drug interactions in addition to drug-acquisition costs. A lack of compliance can lead to treatment failure and an increase in the cost of therapy. Further, adverse effects may increase the treatment costs regardless of any effect on compliance.

Compliance is particularly important in the treatment of chlamydial STDs because an asymptomatic infection, which is common, often involves a sexual partner who may be insufficiently motivated to seek medical attention or receive therapy. Among patients treated with the standard 7-day regimen at an STD clinic, compliance has been estimated at 60%. Additional studies are required to determine whether noncompliance with the 7-day doxycycline treatment results in a high rate of therapeutic failure. Single-dose therapy with azithromycin would most likely ensure a 100% rate of compliance.

**CONCLUSIONS**

Azithromycin, the first member of the azalide subclass of macrolide antibiotics, is distinguished from other macrolides by its extensive penetration into intracellular and interstitial tissue compartments. Although it shares the gram-positive activity of erythromycin, azithromycin is substantially more potent against gram-negative organisms. The prolonged half-life in serum and tissues allows a 5-day, once-daily dosage schedule in the treatment of indicated respiratory-tract and skin and skin-structure infections (unpublished data, Pfizer, Inc., 1996).

Azithromycin, 1 g orally in a single dose, has been recommended by the CDC for the treatment of chlamydial infections, along with the previously recommended regimen of doxycycline, 100 mg orally twice daily for 7 days. Ofloxacin, 300 mg orally twice daily for 7 days, and the older erythromycin regimens are alternatives. A single dose of azithromycin is less expensive than a 7-day regimen of doxycycline or ofloxacin.

Azithromycin has demonstrated better gastrointestinal tolerability than erythromycin. In addition, azithromycin, a pregnancy category-B drug, may be a valid alternative to erythromycin in pregnant patients (unpublished data, Pfizer, Inc., 1996).

**REFERENCES**


AZITHROMYCIN
